Benoit Woessmer, PET Europe CEO at Curium commented, “We are pleased with the growing availability of PYLCLARI® to more nuclear medicine physicians and their patients across Europe. With today’s announcement, we are extremely proud to be improving the choice of diagnostic modalities available to our customers in Germany – ultimately for the benefit of patients with prostate cancer.” In Germany, prostate cancer is the most common cancer among men with around 63,400 new cases diagnosed nationwide every year. Today’s announcement is part of the continued roll-out of PYLCLARI® across the European Union, which is now available for patients with prostate cancer in Greece, Italy, and the Netherlands. For more information about PYLCLARI®: www.pylclari.com Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com Ross Bethell, VP, Head of Global Communications
communications@curiumpharma.com